Generation of an anti-EpCAM antibody and epigenetic regulation of EpCAM in colorectal cancer
نویسندگان
چکیده
منابع مشابه
An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer
Epithelial cell adhesion molecule (EpCAM) is known to be overexpressed in epithelial cancers associated with enhanced malignant potential, particularly colorectal carcinoma (CRC) and head and neck squamous cell carcinoma (HNSCC). However, it is unknown whether progression of malignance can be directly inhibited by targeting EpCAM. Here, we have generated five novel monoclonal antibodies (mAbs) ...
متن کاملExpression of EpCAM and EpCAM variants in human carcinomas
Tyrolean Cancer Research Institute, Innsbruck, Austria Oncotyrol—Center for Personalized Cancer Medicine, Innsbruck, Austria Department of Haematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria Haemato-Oncological Day Hospital, Tappeiner Hospital, Merano, Italy Molecular Pathology Division, Institute of Pathology, University of Basel, Basel, Switzerland Department of Path...
متن کاملThe detection of EpCAM+ and EpCAM– circulating tumor cells
EpCAM expressing circulating tumor cells, detected by CellSearch, are predictive of short survival in several cancers and may serve as a liquid biopsy to guide therapy. Here we investigate the presence of EpCAM(+) CTC detected by CellSearch and EpCAM(-) CTC discarded by CellSearch, after EpCAM based enrichment. EpCAM(-) CTC were identified by filtration and fluorescent labelling. This approach ...
متن کاملConstruction of recombinant Pichia pastoris expressing single-chain antibody fragment against extracellular domain of EpCAM
Introduction: Epithelial cell adhesion molecule (EpCAM) is highly expressed on epithelial tumors. So, EpCAM is a valuable antigen for targeted therapy. Using monoclonal antibodies (mabs) is an attractive approach for targeted cancer therapy. Importantly, limitations of intact mabs including large size led to the development of antibody fragments such as single chain fragment variable (scfv). Pi...
متن کاملFirst surgical experience of intraperitoneal treatment with the trifunctional antibody catumaxomab (anti-EpCam x anti-CD3) for epithelial ovarian cancer.
AIM Intraperitoneal (i.p.) treatment with the trifunctional antibody catumaxomab is a novel promising option in the clinical management of advanced or recurrent epithelial ovarian cancer (EOC). As yet, no data exists sregarding the surgical experience after i.p. catumaxomab application. Therefore we analyzed the surgical outcome of EOC patients, previously treated with i.p. catumaxomab, with sp...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Oncology
سال: 2015
ISSN: 1019-6439,1791-2423
DOI: 10.3892/ijo.2015.2876